AI & Technical question
Abridge has a new AI-assisted clinician workflow whose model quality is improving but still imperfect. What launch criteria would you set before exposing it in live care, how would you combine offline evals, human review, and UX guardrails, and how would you phase the rollout to manage clinical and compliance risk?
- Abridge
- AI & Technical
- Hard
Practice this question out loud. An AI interviewer asks it, follows up like a real interviewer would, and scores your answer. Type or speak.
Start a mock interview on this question · Mock interview from a job description
What this question tests
Whether you can set responsible launch criteria for an imperfect clinical AI feature, combining offline evals, human review, and UX guardrails into one coherent rollout plan rather than treating them as separate checkboxes.
How to approach it
- Set launch criteria as a combination, not a single bar: a minimum offline eval accuracy on clinically relevant categories, a defined human-review rate scaled to current model confidence, and a UX guardrail requiring clear confidence signaling to the clinician.
- Use offline evals built from real clinical documentation cases, weighted toward the error types most costly if missed, like a clinically significant omission, rather than treating all errors as equally weighted.
- Require human review on any output below a confidence threshold, and treat the review requirement as a UX guardrail, not just a backend gate, so clinicians clearly see what still needs their sign-off versus what is higher-confidence.
- Phase the rollout: start with a small set of clinician users on lower-acuity documentation types, expand only after real-world accuracy and clinician override rates confirm offline evals predicted production performance well.
- Manage clinical and compliance risk through the phasing itself: a narrow initial cohort limits blast radius if a failure mode appears that offline evals missed, and gives time to fix it before wider rollout.
What a strong answer includes
- Combines offline evals, human review, and UX guardrails as one integrated launch bar rather than listing them as separate, disconnected requirements.
- Weights eval errors by clinical cost, not uniformly, recognizing that not all model mistakes carry equal risk in a clinical setting.
- Uses phased rollout by acuity level specifically as the risk-management mechanism, connecting the rollout plan directly to limiting real-world harm if something was missed offline.
Common mistakes
- Treats offline eval accuracy as sufficient on its own without connecting it to human review or rollout phasing.
- Weighs all model errors equally instead of prioritizing the clinically costly ones when setting the launch bar.
Likely follow-up questions
- How would you set the confidence threshold that triggers mandatory human review.
- What would make you pause the phased rollout before reaching the full clinician base.
More ai & technical questions
- Abridge has a post-training approach that uses clinician edits, final notes, and EHR context to improve note generation. How would you define the hypotheses, stage gates, and success metrics to take it from offline research to shadow mode to a limited production launch? What evidence would be required at each step to continue, pause, or kill the effort?Abridge · AI & Technical · Hard
- For a model that turns patient-clinician conversations into structured clinical notes, what evaluation suite would you use beyond aggregate quality scores? Specify the failure modes you would prioritize, how you would segment risk by workflow or note type, and the thresholds or escalation paths you would require before declaring the model safe enough to scale.Abridge · AI & Technical · Hard
- Abridge has access to de-identified conversations, clinician edits, final signed notes, EHR context, and downstream care actions, but each signal differs in coverage, cost, bias, and clinical relevance. How would you prioritize which signals to use first for post-training, and what framework would you use to decide whether a sparse, subjective, or expensive signal is still worth operationalizing?Abridge · AI & Technical · Hard
- A chart-aware CDS assistant must feel fast enough for live clinical use while staying reliable and evidence-grounded. How would you work with engineering and ML to define the system tradeoffs and product requirements around latency, retrieval quality, grounding, fallback behavior, and failure handling, and what technical or model-level changes would you prioritize first if response time improved only by reducing answer quality?Abridge · AI & Technical · Hard
- Production monitoring shows a model improves average note quality but increases rare critical errors. How would you investigate whether this is a measurement artifact, a distribution shift, or a real safety regression, and how would you decide between shipping, pausing, rolling back, or narrowing scope?Abridge · AI & Technical · Hard
- Abridge explicitly uses LLM judges, rule-based evaluators, human annotation, and online monitoring. How would you decide which of these methods belongs at each stage of the eval lifecycle, and what failure modes, cost/speed tradeoffs, and confidence limits would you communicate before teams rely on them for launch decisions?Abridge · AI & Technical · Hard
More questions from Abridge
Learn the skill behind it
Chapters of the AI PM course that teach what this question tests.
- Chapter 1: Foundations: the model and the decisions it forces on you
- Chapter 8: Evals: define good and make the number defensible
- Chapter 6: Agents and agentic architecture